Lenalidomide promotes the development of <i>TP53</i>-mutated therapy-related myeloid neoplasms
Adam S. Sperling(Dana-Farber Cancer Institute), Koichi Takahashi(The University of Texas MD Anderson Cancer Center), Vanessa A. Quevedo Barrios(Brigham and Women's Hospital), Feng Wang(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Linda Zhang(Baylor College of Medicine), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Veronica Guerra(Washington University in St. Louis), Yuanqing Yan(Northwestern University), Andrew Nguyen(Broad Institute), Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), P. Andrew Futreal(Wellcome Sanger Institute), Joanne I. Hsu(Brigham and Women's Hospital), Naval Daver(The University of Texas MD Anderson Cancer Center), Benjamin L. Ebert(Dana-Farber Cancer Institute), Marie McConkey(Broad Institute), Curtis Gumbs(The University of Texas MD Anderson Cancer Center), Peter G. Miller(Broad Institute), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Latasha Little(The University of Texas MD Anderson Cancer Center), Jianhua Zhang(XinHua Hospital), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), James A. Kennedy(The University of Adelaide), Ken Furudate(The University of Texas MD Anderson Cancer Center)
Cited by 138
Related Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
|Proceedings of the National Academy of Sciences|2005|56.5k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
The cancer genome
|Nature|2009|3.5k